Trials / Completed
CompletedNCT01966458
A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)
A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare™ Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 494 (actual)
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomized, controlled, unblinded, multi-center evaluation of safety and efficacy in patients implanted with a HeartWare® HVAD who receive improved blood pressure management. Subjects have chronic Stage D or NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy, and who are ineligible for cardiac transplantation.
Detailed description
The study will evaluate non-inferiority of neurologic injury incidence in a new cohort of subjects receiving improved blood pressure management to a control group (i.e., any FDA-approved LVAD for destination therapy). Secondary endpoints include: a comparison of stroke/TIA incidence to a reference observed in the original IDE clinical trial (HW004) that did not specify improved blood pressure management; and non-inferiority of stroke-free success on the originally implanted device to the control group. Subjects will be randomized to HeartWare® HVAD or control LVAD in a 2:1 ratio. Each subject receiving the HeartWare® HVAD or control LVAD is followed to the primary and secondary endpoints at 12 months, with a subsequent follow-up period extending to 60 months post-implant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | HeartWare® VAS (HVAD) | The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use. |
| DEVICE | Control LVAD | Any FDA-approved LVAD for destination therapy. |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-08-01
- Completion
- 2020-08-01
- First posted
- 2013-10-21
- Last updated
- 2020-10-23
- Results posted
- 2018-04-23
Locations
47 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01966458. Inclusion in this directory is not an endorsement.